Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Arch Biopartners (ARCH) Stock Price & Analysis

ARCH Stock Chart & Stats

CA$0.82-CA$0.01(-1.20%)
At close: 9:30 AM EST
C$0.8C$0.9C$1C$1.110 Aug24 Aug8 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
CAD 0.79 - CAD 0.83
52-Week Range
CAD 0.39 - CAD 1.45
Previous Close
CAD 0.83
Volume
N/A
Average Volume (3M)
29.60K
Market Cap
CAD 56.38M
Enterprise Value
CAD 56.39M
Total Cash (Recent Filing)
CAD 2,914
Total Debt (Recent Filing)
CAD 2.73M
Price to Earnings (P/E)
―
Beta
1.20
Next Earnings
Feb 02, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Reduced Losses

Narrower losses indicate some progress in controlling the company’s cost base and preserving capital. Although profitability remains distant, continued improvement could extend financial runway and support development of LSALT while management works toward future clinical and commercial milestones.

Improved Cash Usage

Lower cash consumption is a constructive operating trend for a development-stage biotechnology company. If maintained, improved cash discipline may reduce the pace of external funding needs and allow more of the available capital to support the company’s therapeutic development programs.

Focused Therapeutic Platform

A focused development strategy around inflammatory and ischemia-reperfusion injury gives Arch Biopartners a defined clinical rationale and target area. Concentrating resources on LSALT and related acute-injury applications may help a small biotechnology company build specialized expertise and advance a coherent pipeline.

Bears Say

No Current Revenue

The absence of current revenue means Arch Biopartners has not yet demonstrated commercial demand or an operating revenue base to fund research and development. Persistent annual losses leave performance dependent on future clinical progress and eventual monetization of its product candidate.

Stressed Capitalization

Negative equity and debt that is substantial relative to a very small asset base indicate limited balance-sheet protection. This capitalization reduces financial flexibility, leaves little cushion against setbacks, and increases the company’s dependence on obtaining additional funding to continue operations.

Continued Self-Funding Deficit

Operations continue to consume cash rather than generate it, confirming that the business has not reached self-funding status. Ongoing negative free cash flow can constrain investment in clinical development and require repeated financing before sustainable revenue is established.

Arch Biopartners News

ARCH FAQ

What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was C$0.39 and its highest was C$1.45 in the past 12 months.
What is Arch Biopartners’s market cap?
Arch Biopartners’s market cap is C$56.38M.
When is Arch Biopartners’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arch Biopartners’s earnings last quarter?
Arch Biopartners released its earnings results on Aug 31, 2026. The company reported -C$0.007 earnings per share for the quarter.
Is Arch Biopartners overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 67,933,290 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Arch Biopartners reported an EPS of -C$0.007 in its last earnings report. Following the earnings report the stock price went down -1.942%.
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in TSE:ARCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology